Financial Authorities Probe MBK Partners for Insider Trading in Korea Zinc Takeover Attempt

Reporter Kim Jisun / approved : 2025-01-09 06:48:28
  • -
  • +
  • 인쇄

Photo = FSS

 

 

[Alpha Biz= Kim Jisun] South Korea's financial watchdog has referred MBK Partners to prosecutors for allegedly using undisclosed consulting information in a hostile takeover bid for Korea Zinc. The Financial Supervisory Service (FSS) also uncovered potential stock manipulation during the final day of MBK and Young Poong’s tender offer, marked by large-scale sell-offs that drove Korea Zinc’s stock price downward.

According to industry sources on Wednesday, the FSS submitted the case to prosecutors late last year. MBK Partners is accused of obtaining confidential consulting materials about Korea Zinc’s “Troika Drive” initiative and future business projections. Allegations suggest MBK may have exploited this non-public information in its management dispute with Korea Zinc.

MBK Partners has denied the allegations, arguing that a “Chinese Wall” structure between departments prevented any improper information sharing. However, the FSS reportedly discovered evidence to the contrary, indicating that MBK breached non-disclosure agreements (NDAs) by failing to properly separate information between its investment and management teams.

The investigation also scrutinizes suspicious stock activity on October 14, 2023, the final day of MBK and Young Poong’s public tender offer. On that day, Korea Zinc’s stock price, which was nearing the offer price of ₩830,000, dropped to the mid-₩700,000 range due to unexplained large-scale sell-offs. Korea Zinc suspects this price drop enabled MBK and Young Poong to acquire a larger stake under more favorable conditions.

The allegations, if proven, could have significant implications for MBK Partners, one of Asia’s leading private equity firms, as well as for broader corporate governance practices in South Korea.

 

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

어플

주요기사

Daewoong Pharmaceutical Terminates KRW 384.5 Billion China Supply Deal for Fexuprazan2026.02.13
LG Electronics to Cancel Treasury Shares to Enhance Shareholder Value2026.02.13
Court Sides with Former ADOR CEO Min Hee-jin in First Trial Against HYBE2026.02.13
Nexon Games Swings to Loss in 2025 Amid Revenue Decline and Heavy Development Spending2026.02.13
HD Hyundai Posts Strong Group Earnings, Targets Profit Turnaround at Robotics Unit2026.02.13
뉴스댓글 >

건강이 보이는 대표 K Medical 뉴스

HEADLINE

PHOTO

많이 본 기사